Impaired Turnover of Prolactin Receptor Contributes to Transformation of Human Breast Cells

被引:38
作者
Plotnikov, Alexandr [1 ,2 ]
Varghese, Bentley [1 ,2 ]
Tran, Thai H. [3 ]
Liu, Chengbao [3 ]
Rui, Hallgeir [3 ]
Fuchs, Serge Y. [1 ,2 ]
机构
[1] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA
[2] Univ Penn, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA
[3] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
关键词
E3 UBIQUITIN LIGASE; CANCER CELLS; TRANSGENIC MICE; ACTIVATION; EXPRESSION; CARCINOMA; GROWTH; PROLIFERATION; DEGRADATION; TAXOTERE;
D O I
10.1158/0008-5472.CAN-08-4033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Signaling by polypeptide hormone prolactin (PRL) is mediated by its cognate receptor (PRLr). PRLr is commonly stabilized in human breast cancer due to decreased phosphorylation of residue Ser349, which when phosphorylated recruits the beta Trcp E3 ubiquitin ligase and facilitates PRLr degradation. Here, we show that an impaired PRLr turnover results in an augmented PRL signaling and PRL-induced transcription. Human mammary epithelial cells harboring degradation-resistant PRLr display accelerated proliferation and increased invasive growth. Conversely, a decrease in PRLr levels achieved by either pharmacologic or genetic means in human breast cancer cells dramatically reduced transformation and tumorigenic properties of these cells. Consequences of alteration of PRLr turnover for homeostasis of mammary cells and development of breast cancers, as well as the utility of therapies that target PRLr function in these malignancies, are discussed. [Cancer Res 2009;69(7):3165-72]
引用
收藏
页码:3165 / 3172
页数:8
相关论文
共 45 条
[11]   Cannabimimetic fatty acid derivatives in cancer and inflammation [J].
Di Marzo, V ;
Melck, D ;
De Petrocellis, L ;
Bisogno, T .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2000, 61 (1-2) :43-61
[12]   GSK-3: tricks of the trade for a multi-tasking kinase [J].
Doble, BW ;
Woodgett, JR .
JOURNAL OF CELL SCIENCE, 2003, 116 (07) :1175-1186
[13]   Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter [J].
Fang, Feng ;
Antico, Giovanni ;
Zheng, Jiamao ;
Clevenger, Charles V. .
BMC BIOTECHNOLOGY, 2008, 8 (1)
[14]  
Frontini L, 2004, ANTICANCER RES, V24, P4223
[15]   PROLACTIN RECEPTOR ANTAGONISTS THAT INHIBIT THE GROWTH OF BREAST-CANCER CELL-LINES [J].
FUH, G ;
WELLS, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (22) :13133-13137
[16]   Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study [J].
Gill, S ;
Peston, D ;
Vonderhaar, BK ;
Shousha, S .
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (12) :956-960
[17]   Development and potential clinical uses of human prolactin receptor antagonists [J].
Goffin, V ;
Bernichtein, S ;
Touraine, P ;
Kelly, PA .
ENDOCRINE REVIEWS, 2005, 26 (03) :400-422
[18]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[19]   Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women [J].
Hankinson, SE ;
Willett, WC ;
Michaud, S ;
Manson, JE ;
Colditz, GA ;
Longcope, C ;
Rosner, B ;
Speizer, FE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (07) :629-634
[20]   Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints [J].
Levesque, AA ;
Kohn, EA ;
Bresnick, E ;
Eastman, A .
ONCOGENE, 2005, 24 (23) :3786-3796